EcoDrugPlus

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSRFEG00010021721
Gene Symbol: PSMB4
1 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSRFEG00010001359
Gene Symbol: PSMB5
1 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSRFEG00010015363
Gene Symbol: PSMB6
1 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSRFEG00010010524
Gene Symbol: PSMB7
1 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSRFEG00010012709
Gene Symbol: PSMB8
1 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSRFEG00010012800
Gene Symbol: PSMB9
1 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSRFEG00010019760
Gene Symbol: PSMD2
1 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSRFEG00010021531
Gene Symbol: PSMD4
1 Cross references
282 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSRFEG00010013307
Gene Symbol: PSMC2
1 Cross references
227 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSRFEG00010012635
Gene Symbol: PSMC3
1 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSRFEG00010022017
Gene Symbol: PSMC4
1 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSRFEG00010012523
Gene Symbol: PSMC5
1 Cross references
228 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).